Top

Published in:

28-08-2022 | Thyroid Disease | Original Paper

Clinical characteristics and the treatment modalities of Graves’ orbitopathy in a tertiary referral center in Turkey: changes over two decades

Authors: Mine Ozturk, Onur Konuk, Bercin Tarlan, Mehmet Muhittin Yalcın, Yavuz Kemal Arıbas, Fusun Balos Toruner, Mehmet Unal, Goksun Ayvaz

Published in: International Ophthalmology | Issue 2/2023

Abstract

Purpose

To evaluate the changes in demographics, clinical findings, and treatment modalities in Graves’ orbitopathy (GO) patients at a tertiary referral center in Turkey over the last two decades.

Methods

The clinical data of 752 GO patients were evaluated retrospectively. Patients were divided into 2 groups according to the first ophthalmic examination date; Group 1(n:344) between January 1998 and December 2007 and Group 2(n:408) between January 2008 and December 2017.

Results

The number of nonsmokers was significantly higher in Group 2 (44.0 vs. 26.5%, p < 0.001). The time from the diagnosis of thyroid dysfunction and referral to our center was 32.4 months in Group 1 and 34.8 months in Group 2, (p = 0.166). The most common treatment of hyperthyroidism was antithyroid medications. Radioiodine ablation treatment rate was significantly lower in Group 2 (14.8 vs. 9.1%, p < 0.001). The time between the diagnosis of thyroid disease and orbital involvement was 22.0 vs. 26.6 months in Groups 1 and 2, respectively (p = 0.009). The time elapsed between the diagnosis of orbital disease and referral to our clinic was 21.0 months vs. 22.4 months in Group 1 and 2, respectively (p = 0.068). Orbital disease was most commonly mild, and inactive. Mild and moderate to severe GO and the mean Clinical Activity Score significantly increased, and the rate of sight-threatening disease and orbital decompression surgery significantly decreased in Group 2 (p = 0.042; p < 0.001, respectively).

Conclusions

Mild and inactive orbital disease was the most common form of GO. The severity of GO is declining over the last two decades in Turkey.

Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML (2020) Epidemiology, natural history, risk factors, and prevention of graves’ orbitopathy. Front Endocrinol (Lausanne) 11:615993. https://doi.org/10.3389/fendo.2020.615993CrossRefPubMed

Perros P, Neoh C, Dickinson J (2009) Thyroid eye disease. BMJ 338:b560. https://doi.org/10.1136/bmj.b560CrossRefPubMed

Kahaly GJ (2020) Management of graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgaa646CrossRefPubMedPubMedCentral

European Group of Graves O, Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Mourits MP, Nardi M, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Wiersinga WM (2006) A questionnaire survey on the management of Graves’ orbitopathy in Europe. Eur J Endocrinol 155(2):207–211. https://doi.org/10.1530/eje.1.02201CrossRef

Ippolito S, Cusini C, Lasalvia P, Gianfagna F, Veronesi G, Gallo D, Masiello E, Premoli P, Sabatino J, Mercuriali A, Lai A, Piantanida E, Tanda ML, Bartalena L (2021) Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest 44(8):1707–1718. https://doi.org/10.1007/s40618-020-01479-zCrossRefPubMed

Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98(4):1443–1449. https://doi.org/10.1210/jc.2012-3873CrossRefPubMed

Perros P, Zarkovic M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A, Bournaud C, Brix TH, Covelli D, Ciric S, Daumerie C, Eckstein A, Fichter N, Fuhrer D, Hegedus L, Kahaly GJ, Konuk O, Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Curro N, Dayan C, Dickinson J, Knezevic M, Lane C, Marcocci C, Marino M, Moller L, Nardi M, Neoh C, Pearce S, von Arx G, Toruner FB (2015) PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European group on graves’ orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 99(11):1531–1535. https://doi.org/10.1136/bjophthalmol-2015-306733CrossRefPubMed

European Group on Graves O, Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G (2006) Clinical assessment of patients with Graves’ orbitopathy: the European group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155(3):387–389. https://doi.org/10.1530/eje.1.02230CrossRef

Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R (1989) Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 73(8):639–644. https://doi.org/10.1136/bjo.73.8.639CrossRefPubMedPubMedCentral

10.

Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marino M, Vaidya B, Wiersinga WM, dagger E, (2021) The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185(4):G43–G67. https://doi.org/10.1530/EJE-21-0479CrossRefPubMed

11.

Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G (1991) High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med, 229 (5): 415–420. https://doi.org/10.1111/j.1365-2796.1991.tb00368.x

12.

Todd CH, Allain T, Gomo ZA, Hasler JA, Ndiweni M, Oken E (1995) Increase in thyrotoxicosis associated with iodine supplements in Zimbabwe. Lancet 346(8989):1563–1564. https://doi.org/10.1016/s0140-6736(95)92095-1CrossRefPubMed

13.

Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE (2018) Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 14(5):301–316. https://doi.org/10.1038/nrendo.2018.18CrossRefPubMed

14.

Wiersinga WM (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79(2):145–151. https://doi.org/10.1111/cen.12222CrossRefPubMed

15.

Eckstein A, Quadbeck B, Mueller G, Rettenmeier AW, Hoermann R, Mann K, Steuhl P, Esser J (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87(6):773–776. https://doi.org/10.1136/bjo.87.6.773CrossRefPubMedPubMedCentral

16.

Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA (1996) Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 121(3):284–290. https://doi.org/10.1016/s0002-9394(14)70276-4CrossRefPubMed

17.

Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG, Seah LL, Fong KS, Chee SP, Choo CT, Aw SE (2000) Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 10(12):1093–1100. https://doi.org/10.1089/thy.2000.10.1093CrossRefPubMed

18.

Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A (1989) Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh) 120(4):473–478. https://doi.org/10.1530/acta.0.1200473CrossRefPubMed

19.

Eckstein AK, Losch C, Glowacka D, Schott M, Mann K, Esser J, Morgenthaler NG (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol 93(8):1052–1056. https://doi.org/10.1136/bjo.2007.137265CrossRefPubMed

20.

Bartalena L, Burch HB, Burman KD, Kahaly GJ (2016) A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf) 84(1):115–120. https://doi.org/10.1111/cen.12688CrossRefPubMed

21.

Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Montori VM (2016) Antithyroid drugs-the most common treatment for graves’ disease in the United States: a nationwide population-based study. Thyroid 26(8):1144–1145. https://doi.org/10.1089/thy.2016.0222CrossRefPubMed

22.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves O (2016) The 2016 European thyroid association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5(1):9–26. https://doi.org/10.1159/000443828CrossRef

23.

Ma C, Xie J, Wang H, Li J, Chen S (2016) Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev 2: CD010094. https://doi.org/10.1002/14651858.CD010094.pub2

24.

Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A (1992) Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The thyroid study group. N Engl J Med 326(26):1733–1738. https://doi.org/10.1056/NEJM199206253262603CrossRefPubMed

25.

Li HX, Xiang N, Hu WK, Jiao XL (2016) Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest 39(11):1225–1233. https://doi.org/10.1007/s40618-016-0484-yCrossRefPubMed

26.

Daumerie C, Duprez T, Boschi A (2008) Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitopathy. Eur J Intern Med 19(7):531–536. https://doi.org/10.1016/j.ejim.2008.01.013CrossRefPubMed

27.

Bartley GB (1994) The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92:477–588PubMedPubMedCentral

28.

Wiersinga WM, Bleumink M, Saeed P, Baldeschi L, Prummel MF (2008) Is sleeping position related to asymmetry in bilateral Graves’ ophthalmopathy? Thyroid 18(5):541–544. https://doi.org/10.1089/thy.2007.0302CrossRefPubMed

29.

Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A (2003) Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol 148(5):491–495. https://doi.org/10.1530/eje.0.1480491CrossRefPubMed

30.

Naik MN, Vasanthapuram VH (2021) Demographic and clinical profile of 1000 patients with thyroid eye disease presenting to a Tertiary Eye Care Institute in India. Int Ophthalmol 41(1):231–236. https://doi.org/10.1007/s10792-020-01571-6CrossRefPubMed

31.

Kahaly GJ (2017) Management of Moderately Severe Graves orbitopathy. In: Wiersinga WM Kahaly GJ eds. A Multidisciplinary Approach: Questions and Answers. 3rd edition (revised and expanded) . Karger, Basel, pp 140–176

Title: Clinical characteristics and the treatment modalities of Graves’ orbitopathy in a tertiary referral center in Turkey: changes over two decades
Authors: Mine Ozturk
Onur Konuk
Bercin Tarlan
Mehmet Muhittin Yalcın
Yavuz Kemal Arıbas
Fusun Balos Toruner
Mehmet Unal
Goksun Ayvaz
Publication date: 28-08-2022
Publisher: Springer Netherlands
Keywords: Thyroid Disease
Thyroid Disease
Published in: International Ophthalmology / Issue 2/2023
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-022-02468-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical characteristics and the treatment modalities of Graves’ orbitopathy in a tertiary referral center in Turkey: changes over two decades

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2023

Clinicopathological profile, management and clinical outcomes in recurrent cases of ocular surface squamous neoplasia at a tertiary care centre

Agreement of axial length and anterior segment parameters measured with the MYAH device compared to Pentacam AXL and IOLMaster 700 in myopic children

Ocular surface squamous neoplasia with 360° limbal involvement: a study of 130 patients

Coats disease in India: clinical presentation and outcome in 675 patients (690 Eyes)

Refractive outcomes of scleral-sutured posterior chamber intraocular lenses in post-traumatic eyes

Efficacy of binocular vision training and Fresnel press-on prism on children with esotropia and amblyopia